✦ LIBER ✦

Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST–segment elevation acute coronary syndromes: risk stratification and therapeutic intervention

✍ Scribed by James L Januzzi; Christopher P Cannon; Pierre Theroux; William E Boden

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early Glycoprotein IIb/IIIa Inhibitor Us

✍ James W. Hoekstra; Matthew T. Roe; Eric D. Peterson; Venu Menon; Jyotsna Mulgund 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

Early use of glycoprotein IIb/IIIa inhib

✍ Francis M Fesmire; Eric D Peterson; Matthew T Roe; James F Wojcik 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Glycoprotein IIb-IIIa Inhibitors in the

✍ Cedric W. Lefebvre; James W. Hoekstra; Marc Bonaca; Robert Giugliano 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Use of platelet glycoprotein IIb/IIIa in

✍ Timm Bauer; Helge Möllmann; Franz Weidinger; Uwe Zeymer; Ricardo Seabra-Gomes; F 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 302 KB

Trials of glycoprotein IIb-IIIa inhibito

✍ W. W. Parmley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

Temporal trends in the use of invasive c

✍ Sean Jedrzkiewicz; Shaun G. Goodman; Raymond T. Yan; Robert C. Welsh; Jan Kornde 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 724 KB